Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Operating Expenses (2016 - 2025)

Anaptysbio's Operating Expenses history spans 10 years, with the latest figure at $41.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 21.66% year-over-year to $41.3 million; the TTM value through Dec 2025 reached $186.7 million, down 9.47%, while the annual FY2025 figure was $186.7 million, 9.47% down from the prior year.
  • Operating Expenses reached $41.3 million in Q4 2025 per ANAB's latest filing, down from $41.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $55.3 million in Q1 2025 to a low of $27.7 million in Q3 2021.
  • Average Operating Expenses over 5 years is $41.0 million, with a median of $41.5 million recorded in 2025.
  • Peak YoY movement for Operating Expenses: skyrocketed 56.01% in 2023, then fell 21.66% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $32.2 million in 2021, then rose by 1.91% to $32.8 million in 2022, then surged by 56.01% to $51.1 million in 2023, then increased by 3.21% to $52.8 million in 2024, then decreased by 21.66% to $41.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Operating Expenses are $41.3 million (Q4 2025), $41.6 million (Q3 2025), and $48.4 million (Q2 2025).